Key facts
- It has raised $19.0M; the latest was Grant ($10K) in Nov 2024.
- Notable investors include US National Science Foundation, Service Provider Capital, GingerBread Capital, SteelSky Ventures, Colorado Office of Economic Development & International Trade — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Proov
- ·The full record, as it builds
Funding rounds
No funding rounds for Proov are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Proov
Developer of urine progesterone test strips designed to track ovulation and diagnose hormonal imbalances at home. The company's strips offer a rapid test that measures hormones in the first half of the menstrual cycle and identifies hormonal problems that cause infertility and miscarriage, enabling women to track their hormones with less cost than fertility centers.
- Sector
- Healthcare
- HQ
- Boulder, CO, United States
- Founded
- 2016
- Employees
- 23
- Website
- proovtest.com/
- Ownership
- Privately Held (backing)
Proov doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Proov shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Proov in its N-PORT filings yet. We sweep new filings monthly.